세계의 치료용 핵의학 제품 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Therapeutic Nuclear Medicines was estimated to be worth US$ 3854 million in 2024 and is forecast to a readjusted size of US$ 7460 million by 2031 with a CAGR of 10.4% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Therapeutic Nuclear Medicines cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Therapeutic nuclear medicines are a class of pharmaceuticals that utilize radioactive isotopes to deliver cytotoxic radiation directly to diseased tissues, particularly tumors. These agents combine radioisotopes with targeting molecules-such as peptides, antibodies, or small ligands-to emit alpha, beta, or Auger electrons with high precision. This targeted radiation induces cell death while minimizing damage to surrounding healthy tissues. Therapeutic radiopharmaceuticals are especially promising for cancers that are inoperable or unresponsive to conventional therapies, such as prostate cancer and neuroendocrine tumors. With the rapid advances in precision medicine and molecular imaging, this category is emerging as a pivotal frontier in personalized oncology, offering both clinical efficacy and strong commercial potential.

Driven by the advancement of precision medicine, therapeutic nuclear medicines are gaining momentum as a cornerstone of theranostics. Collaborations between major pharmaceutical companies and radioisotope suppliers are accelerating the development of novel radioligands, while regulatory approvals of breakthrough products are expanding the treatment landscape and attracting investor interest. Government policies supporting isotope production, nuclear logistics, and expedited approvals are further unlocking industry potential and enabling faster translation from R&D to clinical practice.

Despite their clinical promise, therapeutic radiopharmaceuticals face considerable industrial barriers. Radioisotope sourcing is restricted due to national strategic controls, and the supply chain is tightly regulated. Manufacturing and distribution require strict compliance with radiation safety, GMP standards, and cold-chain logistics, resulting in high operational thresholds. Additionally, limited awareness among physicians and patients leads to longer adoption cycles, making education and commercialization efforts critical for new entrants.

As oncology moves toward molecular subtyping and individualized treatment, demand is rising for therapies that offer high efficacy with minimal side effects. Therapeutic nuclear medicines are increasingly incorporated into treatment protocols for advanced-stage cancers. The integration of radiotherapy and diagnostics within hospital platforms is enhancing institutional acceptance and adoption. Meanwhile, global pharmaceutical leaders are accelerating the development of next-generation radiopharmaceuticals across multiple indications, driving broader clinical penetration and application scenarios.

This report aims to provide a comprehensive presentation of the global market for Therapeutic Nuclear Medicines, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Therapeutic Nuclear Medicines by region & country, by Type, and by Application.

The Therapeutic Nuclear Medicines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Therapeutic Nuclear Medicines.

Market Segmentation

By Company

• Cardinal Health
• GE Healthcare
• Lantheus Medical Imaging
• Bayer
• Eli Lilly
• Bracco Imaging
• Curium Pharma
• Jubilant Pharmova
• Aurobindo Pharma
• Novartis
• Siemens
• NTP Radioisotopes
• ANSTO
• Polatom
• China Isotope & Radiation
• Dongcheng Pharma
• Saide Bio

Segment by Type

• Radium-223
• Lutetium-177
• Iodine-131
• Other

Segment by Application

• Thyroid
• Bone Metastasis
• Lymphoma
• Other

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Therapeutic Nuclear Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Therapeutic Nuclear Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Therapeutic Nuclear Medicines in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Therapeutic Nuclear Medicines Product Introduction
• 1.2 Global Therapeutic Nuclear Medicines Market Size Forecast
  • 1.2.1 Global Therapeutic Nuclear Medicines Sales Value (2020-2031)
  • 1.2.2 Global Therapeutic Nuclear Medicines Sales Volume (2020-2031)
  • 1.2.3 Global Therapeutic Nuclear Medicines Sales Price (2020-2031)
• 1.3 Therapeutic Nuclear Medicines Market Trends & Drivers
  • 1.3.1 Therapeutic Nuclear Medicines Industry Trends
  • 1.3.2 Therapeutic Nuclear Medicines Market Drivers & Opportunity
  • 1.3.3 Therapeutic Nuclear Medicines Market Challenges
  • 1.3.4 Therapeutic Nuclear Medicines Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Therapeutic Nuclear Medicines Players Revenue Ranking (2024)
• 2.2 Global Therapeutic Nuclear Medicines Revenue by Company (2020-2025)
• 2.3 Global Therapeutic Nuclear Medicines Players Sales Volume Ranking (2024)
• 2.4 Global Therapeutic Nuclear Medicines Sales Volume by Company Players (2020-2025)
• 2.5 Global Therapeutic Nuclear Medicines Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Therapeutic Nuclear Medicines Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Therapeutic Nuclear Medicines Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Therapeutic Nuclear Medicines
• 2.9 Therapeutic Nuclear Medicines Market Competitive Analysis
  • 2.9.1 Therapeutic Nuclear Medicines Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Therapeutic Nuclear Medicines Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Therapeutic Nuclear Medicines as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Radium-223
  • 3.1.2 Lutetium-177
  • 3.1.3 Iodine-131
  • 3.1.4 Other
• 3.2 Global Therapeutic Nuclear Medicines Sales Value by Type
  • 3.2.1 Global Therapeutic Nuclear Medicines Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Therapeutic Nuclear Medicines Sales Value, by Type (2020-2031)
  • 3.2.3 Global Therapeutic Nuclear Medicines Sales Value, by Type (%) (2020-2031)
• 3.3 Global Therapeutic Nuclear Medicines Sales Volume by Type
  • 3.3.1 Global Therapeutic Nuclear Medicines Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Therapeutic Nuclear Medicines Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Therapeutic Nuclear Medicines Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Therapeutic Nuclear Medicines Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Thyroid
  • 4.1.2 Bone Metastasis
  • 4.1.3 Lymphoma
  • 4.1.4 Other
• 4.2 Global Therapeutic Nuclear Medicines Sales Value by Application
  • 4.2.1 Global Therapeutic Nuclear Medicines Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Therapeutic Nuclear Medicines Sales Value, by Application (2020-2031)
  • 4.2.3 Global Therapeutic Nuclear Medicines Sales Value, by Application (%) (2020-2031)
• 4.3 Global Therapeutic Nuclear Medicines Sales Volume by Application
  • 4.3.1 Global Therapeutic Nuclear Medicines Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Therapeutic Nuclear Medicines Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Therapeutic Nuclear Medicines Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Therapeutic Nuclear Medicines Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Therapeutic Nuclear Medicines Sales Value by Region
  • 5.1.1 Global Therapeutic Nuclear Medicines Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Therapeutic Nuclear Medicines Sales Value by Region (2020-2025)
  • 5.1.3 Global Therapeutic Nuclear Medicines Sales Value by Region (2026-2031)
  • 5.1.4 Global Therapeutic Nuclear Medicines Sales Value by Region (%), (2020-2031)
• 5.2 Global Therapeutic Nuclear Medicines Sales Volume by Region
  • 5.2.1 Global Therapeutic Nuclear Medicines Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Therapeutic Nuclear Medicines Sales Volume by Region (2020-2025)
  • 5.2.3 Global Therapeutic Nuclear Medicines Sales Volume by Region (2026-2031)
  • 5.2.4 Global Therapeutic Nuclear Medicines Sales Volume by Region (%), (2020-2031)
• 5.3 Global Therapeutic Nuclear Medicines Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 5.4.2 North America Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 5.5.2 Europe Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Therapeutic Nuclear Medicines Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 5.7.2 South America Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Therapeutic Nuclear Medicines Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Therapeutic Nuclear Medicines Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Therapeutic Nuclear Medicines Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Therapeutic Nuclear Medicines Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 6.3.2 United States Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 6.4.2 Europe Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 6.5.2 China Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 6.6.2 Japan Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 6.7.2 South Korea Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Therapeutic Nuclear Medicines Sales Value, 2020-2031
  • 6.9.2 India Therapeutic Nuclear Medicines Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Therapeutic Nuclear Medicines Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Cardinal Health
  • 7.1.1 Cardinal Health Company Information
  • 7.1.2 Cardinal Health Introduction and Business Overview
  • 7.1.3 Cardinal Health Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Cardinal Health Therapeutic Nuclear Medicines Product Offerings
  • 7.1.5 Cardinal Health Recent Development
• 7.2 GE Healthcare
  • 7.2.1 GE Healthcare Company Information
  • 7.2.2 GE Healthcare Introduction and Business Overview
  • 7.2.3 GE Healthcare Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 GE Healthcare Therapeutic Nuclear Medicines Product Offerings
  • 7.2.5 GE Healthcare Recent Development
• 7.3 Lantheus Medical Imaging
  • 7.3.1 Lantheus Medical Imaging Company Information
  • 7.3.2 Lantheus Medical Imaging Introduction and Business Overview
  • 7.3.3 Lantheus Medical Imaging Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Lantheus Medical Imaging Therapeutic Nuclear Medicines Product Offerings
  • 7.3.5 Lantheus Medical Imaging Recent Development
• 7.4 Bayer
  • 7.4.1 Bayer Company Information
  • 7.4.2 Bayer Introduction and Business Overview
  • 7.4.3 Bayer Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Bayer Therapeutic Nuclear Medicines Product Offerings
  • 7.4.5 Bayer Recent Development
• 7.5 Eli Lilly
  • 7.5.1 Eli Lilly Company Information
  • 7.5.2 Eli Lilly Introduction and Business Overview
  • 7.5.3 Eli Lilly Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Eli Lilly Therapeutic Nuclear Medicines Product Offerings
  • 7.5.5 Eli Lilly Recent Development
• 7.6 Bracco Imaging
  • 7.6.1 Bracco Imaging Company Information
  • 7.6.2 Bracco Imaging Introduction and Business Overview
  • 7.6.3 Bracco Imaging Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Bracco Imaging Therapeutic Nuclear Medicines Product Offerings
  • 7.6.5 Bracco Imaging Recent Development
• 7.7 Curium Pharma
  • 7.7.1 Curium Pharma Company Information
  • 7.7.2 Curium Pharma Introduction and Business Overview
  • 7.7.3 Curium Pharma Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Curium Pharma Therapeutic Nuclear Medicines Product Offerings
  • 7.7.5 Curium Pharma Recent Development
• 7.8 Jubilant Pharmova
  • 7.8.1 Jubilant Pharmova Company Information
  • 7.8.2 Jubilant Pharmova Introduction and Business Overview
  • 7.8.3 Jubilant Pharmova Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Jubilant Pharmova Therapeutic Nuclear Medicines Product Offerings
  • 7.8.5 Jubilant Pharmova Recent Development
• 7.9 Aurobindo Pharma
  • 7.9.1 Aurobindo Pharma Company Information
  • 7.9.2 Aurobindo Pharma Introduction and Business Overview
  • 7.9.3 Aurobindo Pharma Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Aurobindo Pharma Therapeutic Nuclear Medicines Product Offerings
  • 7.9.5 Aurobindo Pharma Recent Development
• 7.10 Novartis
  • 7.10.1 Novartis Company Information
  • 7.10.2 Novartis Introduction and Business Overview
  • 7.10.3 Novartis Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Novartis Therapeutic Nuclear Medicines Product Offerings
  • 7.10.5 Novartis Recent Development
• 7.11 Siemens
  • 7.11.1 Siemens Company Information
  • 7.11.2 Siemens Introduction and Business Overview
  • 7.11.3 Siemens Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Siemens Therapeutic Nuclear Medicines Product Offerings
  • 7.11.5 Siemens Recent Development
• 7.12 NTP Radioisotopes
  • 7.12.1 NTP Radioisotopes Company Information
  • 7.12.2 NTP Radioisotopes Introduction and Business Overview
  • 7.12.3 NTP Radioisotopes Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 NTP Radioisotopes Therapeutic Nuclear Medicines Product Offerings
  • 7.12.5 NTP Radioisotopes Recent Development
• 7.13 ANSTO
  • 7.13.1 ANSTO Company Information
  • 7.13.2 ANSTO Introduction and Business Overview
  • 7.13.3 ANSTO Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.13.4 ANSTO Therapeutic Nuclear Medicines Product Offerings
  • 7.13.5 ANSTO Recent Development
• 7.14 Polatom
  • 7.14.1 Polatom Company Information
  • 7.14.2 Polatom Introduction and Business Overview
  • 7.14.3 Polatom Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.14.4 Polatom Therapeutic Nuclear Medicines Product Offerings
  • 7.14.5 Polatom Recent Development
• 7.15 China Isotope & Radiation
  • 7.15.1 China Isotope & Radiation Company Information
  • 7.15.2 China Isotope & Radiation Introduction and Business Overview
  • 7.15.3 China Isotope & Radiation Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.15.4 China Isotope & Radiation Therapeutic Nuclear Medicines Product Offerings
  • 7.15.5 China Isotope & Radiation Recent Development
• 7.16 Dongcheng Pharma
  • 7.16.1 Dongcheng Pharma Company Information
  • 7.16.2 Dongcheng Pharma Introduction and Business Overview
  • 7.16.3 Dongcheng Pharma Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.16.4 Dongcheng Pharma Therapeutic Nuclear Medicines Product Offerings
  • 7.16.5 Dongcheng Pharma Recent Development
• 7.17 Saide Bio
  • 7.17.1 Saide Bio Company Information
  • 7.17.2 Saide Bio Introduction and Business Overview
  • 7.17.3 Saide Bio Therapeutic Nuclear Medicines Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.17.4 Saide Bio Therapeutic Nuclear Medicines Product Offerings
  • 7.17.5 Saide Bio Recent Development

8 Industry Chain Analysis

• 8.1 Therapeutic Nuclear Medicines Industrial Chain
• 8.2 Therapeutic Nuclear Medicines Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Therapeutic Nuclear Medicines Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Therapeutic Nuclear Medicines Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer